Go to contents (site navigation)

 


Realised by ALMS™
developer of the AIDS-HIV Reference project
Abstract No.: MoP-265
Session: Small Molecules
Presentation date: Mon, Aug 28, 2006
Presentation time: 09:50 – 11:20

Development and Validation of a Method for the Quantitative Analysis of Moxifloxacin in Human Plasma Using Ultra-performance Liquid Chromatography with Tandem Mass Spectrometric Detection

Jayne M. Spink1, Peter Vince1, Mohammed Abrar1, David Bakes1, Trudi Fletcher1, Barry Hawthorne1

1 Covance Laboratories, Harrogate, United Kingdom

Correspondence address: Jayne M. Spink, Covance Laboratories, Bioanalytical Services, Otley Road, Harrogate, HG3 IPY United Kingdom.

Keywords: Chromatography, Liquid -, High Pressure (HPLC); High Throughput; Mass Spectrometry, Quadrupole; Quantitative Analysis.

Novel aspect: The use of new technology in the form of ultra-performance liquid chromatography for the quantitative analysis of moxifloxacin.

 

Recent advances in silica particle size technology have led to the introduction of Ultra-Performance Liquid Chromatography (UPLC™) systems. The commercial availability of 1.7 µm silica hybrid particles and subsequent advances in pump technology have given significant improvements in chromatographic efficiency, resolution, sensitivity and speed of analysis when compared with conventional High-Performance Liquid Chromatography (HPLC). The high selectivity and sensitivity achieved using the UPLC™ approach minimises sample pre-treatment facilitating high throughput sample analysis.

Moxifloxacin human plasma samples are extracted by protein precipitation and diluted before analysis on a Waters ACQUITY UPLC™ system in combination with a Sciex API 4000 mass spectrometer. A successful validation was achieved with a linear response between 25-5000 ng/mL and precision/ accuracy of < 15% to be used in support of clinical studies.